GANX – gain therapeutics, inc. (US:NASDAQ)

News

Gain Therapeutics (NASDAQ:GANX) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Gain Therapeutics' (GANX) Preclinical Momentum Drives Its Progress in Parkinson's Drug Development [Yahoo! Finance]
Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2025
Gain Therapeutics GAAP EPS of -$0.15 beats by $0.01 [Seeking Alpha]
Gain Therapeutics Reports Financial Results for Third Quarter 2025 and Provides Corporate Update
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com